Diabetic macular edema remains an important cause of vision loss among ... As data from randomized clinical trials accumulate, the precise role for each of these therapies will emerge.

and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is being assessed in pivotal Phase 3 clinical trials to enhance the efficacy of standard anti-VEGF-A therapies.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Patients with a foveal bulge had significantly enhanced visual acuity if they also had resolved diabetic macular edema (DME) ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Diabetic macular edema remains an important cause of visual loss among ... are currently being evaluated in randomized clinical trials. There is an emerging role for pars plana vitrectomy ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...